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Liver cirrhosis is a chronic disease, which may be elicited by viruses (hepatitis
B, C, and D), chronic alcoholism, prolonged obstruction of the bile flow, chronic
exposure to hepatotoxic agents (e.g. drugs or environmental toxins), or inherited
diseases such as hemochromatosis, Wilson's disease, glycogen storage diseases,
and cr,-antitrysin deficiency. The disease is associated with a high mortality, it is
the seventh leading cause of death by disease. The hall-mark of liver cirrhosis is
the excessive deposition of extracellular matrix proteins in the liver. This
process of scarring is called fibrogenesis. The scar tissue that forms in cirrhosis
harms the normal structure of the liver and blocks the flow of blood through the
organ. The loss of functional liver tissue slows the processing of nutrients,
hormones, drugs, and toxins by the liver. Also, the hepatic synthesis of many
proteins and other substances is impaired. The hepatic stellate cells are
predominantly responsible for the enhanced production of extracellular matrix
proteins in the cirrhotic livers.
In this thesis, we used the bile duct ligation (BDL) model in rats as the
experimental model for cirrhosis. This rat model resembles the pathology of
cinhosis in patients, which is caused by a blockade of the bile flow, such as
primary biliary cirrhosis. Other reasons determining our choice for the BDL
model were the quick development of the fibrotic process (within 3 weeks after
ligation), the low mortality of the rats, and the high reproducibility of the
pathological events. In the BDL model, liver injury starts at the portal areas in
contrast o other models of fibrosis, such as CClo intoxication, which is
associated with centrilobular lesions. No model perfectly mimics the human
disease. However, a final common pathway of fibrogenesis in most experimental
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models is the activation of hepatic stellate cells, which is an important feature
for our studies.
To date, no effective antifibrotic drugs are available to reverse the process of
liver cirrhosis. The treatment of patients aim at a limitation of further damage to
the liver or at an attenuation of the complications such as kidney failure, ascites,
or hepatoencephalopathy. In the past decades, a liver transplantation has become
a relevant option for many patients, but the hospital costs and the availability of
donor livers hamper the application of such an operation in general practice. A
pharmacologic intervention would be a better option for antifibrotic therapy, but
as outlined before no adequate antifibrotic drugs are available. To improve the
pharmacological effects of antifibrotic drugs, we aim at a specific delivery of
these drugs to the different cell types in the liver. Therefore, we examined the
cellular specificity of modified albumins in cirrhotic livers. Furthermore, we
developed new carriers that specifically bind to or are taken up into hepatic
stellate cells, the cells that play a key role in the pathogenesis of liver cirrhosis.
Pathology.
Liver cinhosis is a complicated disease, since all resident hepatic cell types are
involved and each cell type plays its own specific role during the progression of
the disease. Initial liver damage usually affects the hepatocytes. As a
consequence, these cells release mediators that activate the Kupffer and
sinusoidal endothelial cells. In addition, the release of chemokines and the
upregulation of adhesion molecules on endothelial cells will induce the
intrahepatic infiltration of inflammatory cells. Kupffer and endothelial cells are
involved in the inflammatory response that sustains throughout the fibrogenic
process. The release of a broad array of cytokines, growth factors, reactive
oxygen species (ROS), and other mediators subsequently activate hepatic stellate
cells. After activation, stellate cells proliferate and migrate into the injured areas
and transdifferentiate into myofibroblast-like cells. These cells are to a major
extent responsible for the enhanced production of the extracellular matrix
proteins (mainly collagen type I and III) that are deposited in the liver tissue.
Insight in the pathogenesis of the disease is necessary to rationally identify the
targets for the carrier and the coupled drugs, and to identify (early) markers that
reflect the severity of the disease. These markers can be applied to evaluate the
effects of therapeutic interventions. Several tissue and plasma markers in
different stages of the disease may serve as early markers. Examples of early
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markers for the fibrotic process are described in chapter 3, in which we studied
the generation of reactive oxygen species (ROS) and nitric oxide radicals (NO)
after induction of fibrosis. ROS (consisting of HrO, and superoxide anions) were
produced at all stages of the disease, but peak levels were observed aI I to 2
weeks after ligation. ROS were mainly detected in the portal areas, the sites
where most inflammatory cells were present, but they were also found in the
parenchymal and necrotic areas of fibrotic livers. In addition to this ROS
staining, we were also able to detect lipid peroxidation products (i.e. 4-
hydroxynonenal adducts) in these fibrotic livers at sites where ROS were
produced.
Furthermore, we showed that an increased production of NO took place in
fibrotic livers due to an upregulation of the enzyme inducible nitric oxide
synthase (iNOS). This enzyme was upregulated immediately after induction of
fibrosis and its expression was present in the portal areas mainly in the
inflammatory cells and in groups of adjacent hepatocytes in the parenchymal
area. In addition, iNOS expression was found in both of these cells types around
necrotic areas. iNOS expression was enhanced early after induction of fibrosis,
that is at four days after ligation. The total hepatic iNOS expression disappeared
at two weeks after ligation.
Since a correlation between NO production and collagen formation has been
suggested, we studied the development of the fibrogenesis after administration
of the iNOS-selective inhibitor S-methylisothiourea in vivo. An inhibition of NO
production did not cause significant differences in the total collagen content of
the liver. In the portal areas where collagen deposition was most prominent in
bile duct ligated rats, no changes were observed in the staining for collagen type
I and III. Only around necrotic areas enhanced staining for collagen type I and
III was found in rats treated with S-methylisothiourea. Therefore, the results
obtained in this study indicate a local and transient anti-fibrotic action of NO
produced by iNOS in fibrotic livers.
The early induction of iNOS and the production of ROS in the fibrotic rat livers
renders these parameters as (early) markers for hepatocyte damage, which may
allow the early detection of therapeutic effects of antifibrotic agents.
Targeting to hepatocytes, endothelial and Kupffer cells.
In the past, modified albumin carriers have been developed that selectively
accumulate in hepatocytes, Kupffer cells, or endothelial cells of the liver. This
cell selectivity was obtained by sugar and charge modification of albumin.
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Lactosylation, mannosylation, and succinylation are standard modification
procedures for the targeting to the above mentioned hepatic cells. The cellular
selectivity of these modified albumins was predominantly examined in healthy
animals. Therefore, we started our project by evaluating the organ and
intrahepatic distribution of these modified albumins in rats with fully developed
liver fibrosis, that is, three weeks after ligation of the bile duct. The distribution
characteristics and kinetic parameters were nearly identical in healthy and
diseased rats which demonstrates the applicability of these macromolecules for
the targeting of drugs to the different cells in the cinhotic livers (Chapter 4).
Targeting to hepatic stellate cells.
Hepatic stellate cells are the key cells involved in the formation of tlie
extracellular matrix proteins. Moreover, these (activated) cells produce an array
of mediators that enhance and sustain the fibrotic process independently from
the activity of Kupffer, endothelial, and inflammatory cells. This central role for
hepatic stellate cells prompts the development of agents that interfere with the
activation of this cell type. Targeting of antifibrotic agents using albumin
carriers is an option to obtain a selective drug accumulation in activated hepatic
stellate cells. Until recently, no carrier molecule was available that distributed to
stellate cells. Therefore, we developed carriers that interacted with membrane
receptors on stellate cells, which are upregulated after activation of this cell type.
Since a strong upregulation of the mannose 6-phosphate/insulin-like growth
factor Il receptor was reported on the cell membrane of activated stellate cells,
we modified albumin with mannose 6-phosphate groups (M6P,-HSA). An
increase in the degree of mannose 6-phosphate substitution on the core protein
albumin induced a parallel increase in the hepatic stellate cell-specific
accumulation in vivo in rats with liver fibrosis. M6P--HSA with a low degree of
sugar loading (x<10) remained in the plasma (>75oh of the administrated ose),
whereas an increase in the molar ratio of M6P:HSA to 28:l caused an
preferential accumulation in the liver (59+9%o f the administrated i.v. dose at
t:10 min). Studies on the in vit'o intrahepatic distribution of M6P--HSA
revealed that 70+1 1o/o f the intrahepatic staining for M6Pz*-HSA was found in
hepatic stellate cells (Chapter 5). In vitro studies confirmed the binding of
M6P28-HSA to rat hepatic stellate cells, in particular to primary cultures of
activated hepatic stellate cells. Results demonstrated that M6P28-HSA binds to
specific receptors on the target-cells. Furlhemrore, rapid internalization of
M6P28-HSA was demonstrated that occurred via the endosomal/lysosomal
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pathway. Similar results regarding binding and uptake were obtained in studies
with slices prepared from human livers. Sinusoidal endothelial cells were
responsible for the hepatic uptake of M6Pr'-HSA in normal human livers,
whereas hepatic stellate cells contributed primarily to the uptake of this
neoglycoprotein in cirrhotic human livers (Chapter 6).
New carriers to hepatic stellate cells were designed based on the use of cyclic
peptides that recognize specific receptors on these target-cells. We selected the
collagen type VI and platelet derived growth factor (PDGF) receptors, since the
expression of these receptors is upregulated on stellate cell membranes during
fibrosis. Cyclic peptides were prepared that contained the amino acid sequence
recognizing the receptors of collagen type VI and PDGF-BB. The use of
peptides as homing devices to gain access to target cells is a new concept
described in this thesis and a patent application on this subject has recently been
filed by us (Appendix).
In chapter 7, the results obtained with the carrier pCVI-HSA are described.
Albumin substituted with RGD containing cyclic peptides displayed a specific
interaction with hepatic stellate cells in vitro and in vivo. pCVI-HSA was taken
up in activated hepatic stellate cells, although at a slower rate and to a lesser
extent as M6Prr-HSA. ir vivo results showed preferential accumulation of pCVI-
HSA in fibrotic and normal rat livers, respectively 62t6% and 75tI6Yo of the
dose was found in this organ 10 min after administration. Subsequent analysis of
these livers demonstrated that in fibrotic livers 73+14Yo f the hepatic cells that
bound the carrier could be identified as hepatic stellate cells, whereas endothelial
cells contributed mostly to the total liver uptake of pCVI-HSA in normal rats.
The peptide niodified albumin pPB-HSA was studied for its applicability as a
stellate celi-specific carrier via binding to the PDGF receptor (Chapter 8).
Specific binding of pPB-HSA to PDGF receptors was demonstrated by
perfomring conrpetition studies in fibroblast cultures with native PDGF-BB ('25I
labelled) and increasing amounts of pPB-HSA. In vivo experiments established
the liver specific distribution of pPB-HSA in normal rats and in rats with liver
fibrosis. Moreover, hepatic stellate cells largely contributed to this hepatic
uptake in fibrotic livers after intravenous injection. In vitro studies confirmed the
binding of pPB-HSA to primary cultures of rat hepatic stellate cells, in particular




The studies presented in this thesis demonstrate the applicability of modified
abumins as drug carriers to cells in cirrhotic livers. Now all hepatic cell types,
each of them playing a role in the development of liver fibrosis, can be
specifically targeted using modified albumins. Derivatization of albumin with
lactose, mannose, or succinic acid resulted in specific distribution to respectively
hepatocytes, Kupffer cells, or endothelial cells in fibrotic livers. The lack of cell-
selective drug carriers to hepatic stellate cells at the beginning of our project is
now compensated by the availability of three different types of carriers. Whether
neoglycoproteins or peptide-modified albumins represent the most optimal
carrier remains to be established. The carriers M6P^-HSA, pCVI-HSA, and
pPB-HSA all allow cell-specific delivery of antifibrotic agents to hepatic stellate
cells. Since the mannose 6-phosphate/insulin-like growth factor II receptor and
the amino acid sequences recognizing the collagen type VI and PDGF receptors
are similar in rats and in humans, these carriers may be applicable in patients as
well. Further research is warranted to explore the possibilities of drug targeting
in cirrhotic patients.
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